Le Lézard
Classified in: Health, Science and technology
Subject: Lawsuit

BioSpyder Files Action Against HTG Molecular Diagnostics in Federal Court


On Wednesday, August 12, 2020, BioSpyder Technologies, Inc. ("BioSpyder") filed a civil action in the federal court for the Northern District of California, seeking a declaratory judgment that the BioSpyder TempO-Seq gene expression profiling assay does not infringe any valid claim in U.S. Patent No. 8,741,564 ("the '564 patent") for Quantitative Nuclease Protection Assay (QNPA) and Sequencing (QNPS) Improvements.

HTG Molecular Diagnostics, Inc. ("HTG") has repeatedly and baselessly asserted that BioSpyder has infringed the '564 patent. To counter HTG's unfounded and reckless allegations of patent infringement, BioSpyder filed the declaratory judgment action to vindicate itself and its technology. BioSpyder looks forward to establishing the fact that it does not infringe any valid claim of the '564 patent.

BioSpyder respects all valid intellectual property rights, takes intellectual property rights very seriously, and has its own portfolio of patents. "Since our founding in 2011, BioSpyder has respected the intellectual property of those who have blazed a trail before us," said Joel McComb, CEO of BioSpyder. "Simply put, we view the actions of HTG as reckless and baseless, and with this action are putting HTG on notice that we will vigorously defend our premier technology and intellectual property."

About BioSpyder Technologies, Inc.

BioSpyder Technologies is based in Carlsbad, California and is a privately held company serving the Research, Diagnostic, Toxicology, Single Cell, and Drug Discovery markets. BioSpyder is the developer of TempO-SeqTM, a targeted gene expression technology which applies up to whole transcriptome analysis from sample types such as purified DNA/RNA, FFPE, single cells, whole blood, and whole organisms. In addition to providing kits and services to its customers, BioSpyder is focused on developing innovative applications of the TempO-Seq core technology both internally and through diagnostic partners. More information about BioSpyder Technologies, Inc. is available at www.biospyder.com.

Case #4:20-cv-05607


These press releases may also interest you

at 03:40
TUC S.r.l., the Deep Tech Company known for TUC.technology, launches a fundamental evolution of its offer, TUC.tinytm. This mobility revolution comes with all the features at the base of the TUC.technology patent, issued in over 140 countries...

at 03:38
Allied Market Research published a report, titled, "Virtual Tour Market by Type (360 Virtual...

at 03:30
Bloomberg today announced that the first electronic list trade in European Government Bonds was executed on Bloomberg's Multilateral Trading Facility (MTF) referencing Bloomberg's Evaluated Pricing Service (BVAL) as the closing price. The trade was...

at 03:29
OKX, a leading Web3 technology company, has issued updates for April 24, 2024. OKX Wallet Now Integrated with Snotra OKX Wallet has...

at 03:15
The Explorers Club and Expanding World, are thrilled to announce the fifth edition of The GLEX Summit, known as the 'Davos of Exploration,' set to take place from June 15 to 19 on Porto city and Terceira Island in the Azores, Portugal....

at 03:05
Attentive, the AI marketing platform for leading brands, has seen 128% revenue growth in the UK over the last year and has doubled the size of its UK team. The company's momentum underscores the market's continued demand for personalised SMS...



News published on and distributed by: